DEPO-PROVERA (medroxyprogesterone acetate) by Pfizer is suspension, usp inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. Approved for contraception, endometriosis, menorrhagia. First approved in 1992.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
DEPO-PROVERA (medroxyprogesterone acetate) is a long-acting injectable progestin that inhibits gonadotropin secretion to prevent ovulation and thicken cervical mucus, primarily used for contraception. The product is indicated across a broad range of conditions including contraception, endometriosis, menorrhagia, endometrial hyperplasia, and hormone-responsive cancers. It represents a foundational hormonal therapy with decades of clinical use and established safety profile.
Mature product nearing loss of exclusivity with minimal Medicare claims, indicating small team size and reduced investment focus compared to peak-cycle competitors.
Suspension, USP inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.
Worked on DEPO-PROVERA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate
Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle
Randomized Control Trial Copper Intrauterine Device and Depo-medroxyprogesterone Acetate (DMPA) of HIV+ Women in Malawi
Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moDEPO-PROVERA offers limited career growth given its LOE-approaching status and minimal linked job openings; roles are primarily focused on maintaining market share and managing decline. Career professionals should view this assignment as a stabilizing defensive role rather than a launch or growth opportunity.